Cantor Fitzgerald Said 'Just the Beginning' of CymaBay Therapeutic (CBAY) Share Recovery After FDA Hold Lifted
Tweet Send to a Friend
Cantor Fitzgerald analyst Eliana Merle reiterated an Overweight rating and $15.00 price target on CymaBay Therapeutic (NASDAQ: CBAY) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
